Medipal and Sony Innovation Fund by IGV were among the investors that boosted the liver disease drug spinout's latest round to $52.6m.
Promethera Biosciences, a Belgium-based liver-transplantation drug spinout of Université catholique de Louvain, increased its series D round to €47.2m ($52.6m) on Monday, adding €7.5m in a tranche co-led by an investment vehicle for electronics manufacturer Sony.
Sony Innovation Fund by IGV co-led the tranche with venture capital firm Pegasus Tech Ventures, investing alongside medical supplies distributor Medipal Holdings, family office Six Snow and two unnamed private investors.
Trading group Itochu supplied the initial $11.3m before Mitsui &…
